肾康注射液联合厄贝沙坦对糖尿病肾病微量白蛋白的影响

目的：观察肾康注射液联合厄贝沙坦对早期糖尿病肾病患者24h尿微量白蛋白排泄率（Urinary Albumin Excretion Rate UAER）、血脂及血液流变性的影响。方法：将150例血压正常的早期糖尿病肾病患者随机分为对照组、肾康注射液组、肾康注射液加厄贝沙坦联合组，比较三组患者治疗前后UAER、血脂及血液流变学指标的变化。结果：治疗9周后，肾康注射液组和联合组在降低患者24h尿微量白蛋白排泄率、降低血脂及改善患者血液流变性方面均好于治疗前（P〈0．01），且明显优于对照组（P〈0．05），对照组改善情况不明显；肾康注射液加厄贝沙坦联合组在降低患者UAER、血脂及改善血液流变性方面，明显优于单用肾康注射液组（P〈0．05）。结论：肾康注射液可减少早期糖尿病肾病患者UAER，降低血脂，改善患者血液流变性，对早期糖尿病肾病具有治疗作用，且与厄贝沙坦合用可能有协同作用。

Influence of Shenkang Injection Combined with Irbesartan on Trace Albumin Excretion and Blood Rheology of Early Diabetic Nephropathy Patients

Objective： To observe the influence of Shenkang injection combined with irbesartan on urinary albumin excretion rate （UAER） within 24 hours, serum lipid, and blood rheology of patients with early diabetic nephropathy. Methods： One hundred and fifty normotensive early diabetic nephropathy patients were randomly divided into control group （group C）, Shenkang injection group （group S） and Shenkang and Irbesartan combination group （group SI）. All of them were given diabetic education, and carried out dietary regimen, and suitable movement. In the same time, oral anti-hyperglycemic agents were given to them till their fasting blood glucose （FBG） was less than 7.0 mmol/L and postprandial blood glucose （PBG） less than 10.0 mmol/L. Besides, patients in group C were treated with oral anti-hyperglycemic agents or/and insulin, those in group S were treated with Shenkang injection 100 ml mixed with 5% glucose 250 -300 ml plus 2 -3 U of insulin intravenously guttaed once a day, and those in group SI were treated like group S but plus Irbesartan 0.15 g once a day orally. A treat- ment course was 3 weeks and the experiment lasted 3 courses. The levels of UAER, serum lipid and blood rheology were detected and compared before and after the treatment. Results： UAER, and serum lipid of patients in groups S and SI after treatment were significantly lower than those before and their blood theology indexes were improved （P 〈0.01 ）. All the improvements were better than those in control group （ P 〈 0.05 ）, of which the amelioration of the disease was not obvious. The improvements in group reduce UAER, nephropathy in Key words] SI were better than those in group S （ P 〈 0. 05 ）. Conclusions： Shenkang injection can decrease serum lipid, and improve renal blood rheology. It effectively prevents diabetic earlier period and may have jolnt-action with Irbesartan.